Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05798897 · ClinicalTrials.gov registry record · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
A Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by Marker Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
- 7
- Study locations
NCT05798897: Recruiting Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by Marker Therapeutics.
NCT05798897 is a Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma that is actively recruiting participants, run by Marker Therapeutics. The registered enrollment target is 79 participants, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (53% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05798897, a Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, is actively recruiting participants, sponsored by Marker Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
Primary Outcome
To assess safety and tolerability of escalating doses of MT-601 by the number of participants with MT-601 Dose Limiting Toxicities (DLTs) and Safety events (including but not limited to): treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), deaths, and clinical laboratory abnormalities per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
Conditions Studied
Interventions
- DRUG MT-601
Study Locations (7)
Colorado
- University of Colorado - Aurora
- Colorado Blood Cancer Institute (Sarah Cannon) - Denver
California
- City of Hope - Duarte
Kansas
- University of Kansas Medical Center - Kansas City
New York
- Cornell - New York
Texas
- Sarah Cannon Research Institute at St. David's South Austin - Austin
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2023-01-02 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 1 |
What NCT05798897 shows while recruiting
NCT05798897 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (53% lower).
The record links to 7 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which MT-601 is the first listed.
NCT05798897 lists 7 locations in 6 states (Colorado, California, Kansas).
Frequently Asked Questions
What is clinical trial NCT05798897 about?
NCT05798897 is a clinical study titled "Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma". This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
What is the current status of trial NCT05798897?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2023-01-02. Estimated completion is 2028-02-28.
What conditions does trial NCT05798897 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory.
What interventions are being tested in trial NCT05798897?
The interventions under investigation include: MT-601 (DRUG).
Who is sponsoring clinical trial NCT05798897?
This trial is sponsored by Marker Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05798897 being conducted?
This trial has 7 study locations across California, Colorado, Kansas, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05798897's enrollment target sits among peer trials
79 44th of 106 higher than 63 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI